Evidence map›Paper›PMID 41888301›Full record

ArticleScientific reports2026

Mesenchymal to epithelial transition (MET) in cancer progression: insights from logical modeling.

Sophia Orozco-Ruiz, Marco Ruscone, Emmanuel Barillot, Olivier Destaing, Laurence Calzone

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sophia Orozco-RuizInstitut Curie, Université PSL, 75005, Paris, France. sophia.orozco-ruiz@curie.fr.
Marco RusconeInstitut Curie, Université PSL, 75005, Paris, France.
Emmanuel BarillotInstitut Curie, Université PSL, 75005, Paris, France.
Olivier DestaingInstitute for Advanced Biosciences, University Grenoble Alpes, INSERM 1209, CNRS UMR5309, Grenoble, France.
Laurence CalzoneInstitut Curie, Université PSL, 75005, Paris, France. Laurence.calzone@curie.fr.

Funding

European Union's Horizon Europe research and innovation program n101136379
6 · The paper itself

Abstract

The ability of carcinoma cells to transition along the epithelial-mesenchymal spectrum is crucial for metastasis. While the process of Epithelial to Mesenchymal Transition (EMT) has widely been studied, its reverse, Mesenchymal to Epithelial Transition (MET), has been less thoroughly explored. Here, we first present a comprehensive overview of the known MET inducers in cancer, detailing the cellular contexts in which they play a role and their interactions with EMT drivers. Based on these observations, we constructed a minimal regulatory network centered on key signaling pathways, including Transforming Growth Factor β (TGFβ), Bone morphogenetic protein (BMP), and other growth factors. This network was then translated into a logical model to explore the dynamic interplay between EMT and MET programs. Through in silico simulations, we demonstrate how perturbing this network can interfere with EMT programs to induce MET. Our findings highlight that the MET process is highly dependent on the mesenchymal context. We further demonstrate that persistence of EMT programs constrains how far along the epithelial–mesenchymal spectrum different MET inducers can reposition mesenchymal cells. Moreover, perturbing components of one EMT program can reinforce alternative EMT pathways, thereby preserving this balance and preventing a full reversion to epithelial states, highlighting a new function for cells with hybrid states.

Indexed as

Epithelial-Mesenchymal TransitionModels, BiologicalNeoplasmsAnimalsBone Morphogenetic ProteinsComputer SimulationDisease ProgressionHumansSignal TransductionTransforming Growth Factor betaBone Morphogenetic ProteinsTransforming Growth Factor beta

Identifiers

PMID41888301
PMCPMC13172524

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.